Main fields of research are clinical trials with prophylactic HPV vaccines and HPV related cancer and precancer. As special focus is on vulvar disease.
- Joura, E.A. et al., 2015. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine, 372(8), pp.711-723. Available at: http://dx.doi.org/10.1056/NEJMoa1405044.
- Joura, E.A. et al., 2012. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ, 344(mar27 3), pp.e1401-e1401. Available at: http://dx.doi.org/10.1136/bmj.e1401.
- Joura, E.A. et al., 2008. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine, 26(52), pp.6844-6851. Available at: http://dx.doi.org/10.1016/j.vaccine.2008.09.073.
- Joura, E.A. et al., 2007. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. The Lancet, 369(9574), pp.1693-1702. Available at: http://dx.doi.org/10.1016/S0140-6736(07)60777-6.